APO Research
Talk to an analyst

APO RESEARCH · REPORT

Leukocyte Surface Antigen CD47

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Leukocyte Surface Antigen CD47 Market Outlook and Growth Opportunities 2026

22 December 2025192 pages

Choose your research edition.

Industry ResearchLeukocyte Surface Antigen CD47 Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Leukocyte Surface Antigen CD47 Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal Leukocyte Surface Antigen CD47 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Leukocyte Surface Antigen CD47 Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Leukocyte Surface Antigen CD47 Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Leukocyte Surface Antigen CD47 market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Leukocyte Surface Antigen CD47 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Leukocyte Surface Antigen CD47 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Leukocyte Surface Antigen CD47 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Leukocyte Surface Antigen CD47 market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Leukocyte Surface Antigen CD47 market include Trillium Therapeutics Inc, Surface Oncology Inc, Forty Seven Inc, Celgene Corp and Aurigene Discovery Technologies Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Leukocyte Surface Antigen CD47 market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Leukocyte Surface Antigen CD47 and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Leukocyte Surface Antigen CD47 sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Leukocyte Surface Antigen CD47 market size, projected growth trends, production technologies, key applications, and end-use industries.

Leukocyte Surface Antigen CD47 Segment by Company

Trillium Therapeutics Inc

Surface Oncology Inc

Forty Seven Inc

Celgene Corp

Aurigene Discovery Technologies Ltd

Leukocyte Surface Antigen CD47 Segment by Type

PSTx-23

CC-90002

B-6H12

ALX-148

Others

Leukocyte Surface Antigen CD47 Segment by Application

Ischemia Reperfusion Injury

Kindney Transplant Rejection

Ovarian Cancer

Lymphoma

Others

Leukocyte Surface Antigen CD47 Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Leukocyte Surface Antigen CD47 status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Leukocyte Surface Antigen CD47 market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Leukocyte Surface Antigen CD47 significant trends, drivers, influence factors in global and regions.

6. To analyze Leukocyte Surface Antigen CD47 competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Leukocyte Surface Antigen CD47 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Leukocyte Surface Antigen CD47 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Leukocyte Surface Antigen CD47.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Leukocyte Surface Antigen CD47 market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Leukocyte Surface Antigen CD47 industry.

Chapter 3: Detailed analysis of Leukocyte Surface Antigen CD47 manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Leukocyte Surface Antigen CD47 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Leukocyte Surface Antigen CD47 in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Leukocyte Surface Antigen CD47 Industry Trends Table 2. Leukocyte Surface Antigen CD47 Industry Drivers Table 3. Leukocyte Surface Antigen CD47 Industry Opportunities and Challenges Table 4. Leukocyte Surface Antigen CD47 Industry Restraints Table 5. Global Leukocyte Surface Antigen CD47 Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Leukocyte Surface Antigen CD47 Revenue Share by Company (2021-2026) Table 7. Global Leukocyte Surface Antigen CD47 Sales Volume by Company (k units) & (2021-2026) Table 8. Global Leukocyte Surface Antigen CD47 Sales Volume Share by Company (2021-2026) Table 9. Global Leukocyte Surface Antigen CD47 Average Price (US$/unit) of Company (2021-2026) Table 10. Global Leukocyte Surface Antigen CD47 Company Ranking, (2024-2026) & (USD Million) Table 11. Global Leukocyte Surface Antigen CD47 Key Company Manufacturing Base & Headquarters Table 12. Global Leukocyte Surface Antigen CD47 Company, Product Type & Application Table 13. Global Leukocyte Surface Antigen CD47 Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Leukocyte Surface Antigen CD47 by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of PSTx-23 Table 18. Significant Companies of CC-90002 Table 19. Significant Companies of B-6H12 Table 20. Significant Companies of ALX-148 Table 21. Significant Companies of Others Table 22. Global Leukocyte Surface Antigen CD47 Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 23. Global Leukocyte Surface Antigen CD47 Sales Volume by Type (2021-2026) & (k units) Table 24. Global Leukocyte Surface Antigen CD47 Sales Volume by Type (2027-2032) & (k units) Table 25. Global Leukocyte Surface Antigen CD47 Sales Volume Share by Type (2021-2026) Table 26. Global Leukocyte Surface Antigen CD47 Sales Volume Share by Type (2027-2032) Table 27. Global Leukocyte Surface Antigen CD47 Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Leukocyte Surface Antigen CD47 Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Leukocyte Surface Antigen CD47 Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Leukocyte Surface Antigen CD47 Sales Value Share by Type (2021-2026) Table 31. Global Leukocyte Surface Antigen CD47 Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Ischemia Reperfusion Injury Table 33. Significant Companies of Kindney Transplant Rejection Table 34. Significant Companies of Ovarian Cancer Table 35. Significant Companies of Lymphoma Table 36. Significant Companies of Others Table 37. Global Leukocyte Surface Antigen CD47 Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global Leukocyte Surface Antigen CD47 Sales Volume by Application (2021-2026) & (k units) Table 39. Global Leukocyte Surface Antigen CD47 Sales Volume by Application (2027-2032) & (k units) Table 40. Global Leukocyte Surface Antigen CD47 Sales Volume Share by Application (2021-2026) Table 41. Global Leukocyte Surface Antigen CD47 Sales Volume Share by Application (2027-2032) Table 42. Global Leukocyte Surface Antigen CD47 Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Leukocyte Surface Antigen CD47 Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global Leukocyte Surface Antigen CD47 Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global Leukocyte Surface Antigen CD47 Sales Value Share by Application (2021-2026) Table 46. Global Leukocyte Surface Antigen CD47 Sales Value Share by Application (2027-2032) Table 47. Global Leukocyte Surface Antigen CD47 Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 48. Global Leukocyte Surface Antigen CD47 Sales by Region (2021-2026) & (k units) Table 49. Global Leukocyte Surface Antigen CD47 Sales Market Share by Region (2021-2026) Table 50. Global Leukocyte Surface Antigen CD47 Sales by Region (2027-2032) & (k units) Table 51. Global Leukocyte Surface Antigen CD47 Sales Market Share by Region (2027-2032) Table 52. Global Leukocyte Surface Antigen CD47 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Leukocyte Surface Antigen CD47 Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global Leukocyte Surface Antigen CD47 Sales Value Share by Region (2021-2026) Table 55. Global Leukocyte Surface Antigen CD47 Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global Leukocyte Surface Antigen CD47 Sales Value Share by Region (2027-2032) Table 57. Global Leukocyte Surface Antigen CD47 Market Average Price (US$/unit) by Region (2021-2026) Table 58. Global Leukocyte Surface Antigen CD47 Market Average Price (US$/unit) by Region (2027-2032) Table 59. Global Leukocyte Surface Antigen CD47 Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 60. Global Leukocyte Surface Antigen CD47 Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Leukocyte Surface Antigen CD47 Sales by Country (2021-2026) & (k units) Table 62. Global Leukocyte Surface Antigen CD47 Sales Market Share by Country (2021-2026) Table 63. Global Leukocyte Surface Antigen CD47 Sales by Country (2027-2032) & (k units) Table 64. Global Leukocyte Surface Antigen CD47 Sales Market Share by Country (2027-2032) Table 65. Global Leukocyte Surface Antigen CD47 Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global Leukocyte Surface Antigen CD47 Sales Value Market Share by Country (2021-2026) Table 67. Global Leukocyte Surface Antigen CD47 Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global Leukocyte Surface Antigen CD47 Sales Value Market Share by Country (2027-2032) Table 69. Trillium Therapeutics Inc Company Information Table 70. Trillium Therapeutics Inc Business Overview Table 71. Trillium Therapeutics Inc Leukocyte Surface Antigen CD47 Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Trillium Therapeutics Inc Leukocyte Surface Antigen CD47 Product Portfolio Table 73. Trillium Therapeutics Inc Recent Development Table 74. Surface Oncology Inc Company Information Table 75. Surface Oncology Inc Business Overview Table 76. Surface Oncology Inc Leukocyte Surface Antigen CD47 Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Surface Oncology Inc Leukocyte Surface Antigen CD47 Product Portfolio Table 78. Surface Oncology Inc Recent Development Table 79. Forty Seven Inc Company Information Table 80. Forty Seven Inc Business Overview Table 81. Forty Seven Inc Leukocyte Surface Antigen CD47 Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Forty Seven Inc Leukocyte Surface Antigen CD47 Product Portfolio Table 83. Forty Seven Inc Recent Development Table 84. Celgene Corp Company Information Table 85. Celgene Corp Business Overview Table 86. Celgene Corp Leukocyte Surface Antigen CD47 Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Celgene Corp Leukocyte Surface Antigen CD47 Product Portfolio Table 88. Celgene Corp Recent Development Table 89. Aurigene Discovery Technologies Ltd Company Information Table 90. Aurigene Discovery Technologies Ltd Business Overview Table 91. Aurigene Discovery Technologies Ltd Leukocyte Surface Antigen CD47 Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Aurigene Discovery Technologies Ltd Leukocyte Surface Antigen CD47 Product Portfolio Table 93. Aurigene Discovery Technologies Ltd Recent Development Table 94. Key Raw Materials Table 95. Raw Materials Key Suppliers Table 96. Leukocyte Surface Antigen CD47 Distributors List Table 97. Leukocyte Surface Antigen CD47 Customers List Table 98. Research Programs/Design for This Report Table 99. Authors List of This Report Table 100. Secondary Sources Table 101. Primary Sources List of Figures Figure 1. Leukocyte Surface Antigen CD47 Product Image Figure 2. Global Leukocyte Surface Antigen CD47 Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Leukocyte Surface Antigen CD47 Sales Value (2021-2032) & (US$ Million) Figure 4. Global Leukocyte Surface Antigen CD47 Sales (2021-2032) & (k units) Figure 5. Global Leukocyte Surface Antigen CD47 Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Leukocyte Surface Antigen CD47 Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. PSTx-23 Image Figure 10. CC-90002 Image Figure 11. B-6H12 Image Figure 12. ALX-148 Image Figure 13. Others Image Figure 14. Global Leukocyte Surface Antigen CD47 Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Leukocyte Surface Antigen CD47 Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Leukocyte Surface Antigen CD47 Sales Volume Share by Type (2021-2032) Figure 17. Global Leukocyte Surface Antigen CD47 Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Leukocyte Surface Antigen CD47 Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Leukocyte Surface Antigen CD47 Sales Value Share by Type (2021-2032) Figure 20. Ischemia Reperfusion Injury Image Figure 21. Kindney Transplant Rejection Image Figure 22. Ovarian Cancer Image Figure 23. Lymphoma Image Figure 24. Others Image Figure 25. Global Leukocyte Surface Antigen CD47 Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 26. Global Leukocyte Surface Antigen CD47 Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global Leukocyte Surface Antigen CD47 Sales Volume Share by Application (2021-2032) Figure 28. Global Leukocyte Surface Antigen CD47 Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Leukocyte Surface Antigen CD47 Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global Leukocyte Surface Antigen CD47 Sales Value Share by Application (2021-2032) Figure 31. Global Leukocyte Surface Antigen CD47 Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 32. Global Leukocyte Surface Antigen CD47 Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global Leukocyte Surface Antigen CD47 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global Leukocyte Surface Antigen CD47 Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Leukocyte Surface Antigen CD47 Sales Value (2021-2032) & (US$ Million) Figure 36. North America Leukocyte Surface Antigen CD47 Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe Leukocyte Surface Antigen CD47 Sales Value (2021-2032) & (US$ Million) Figure 38. Europe Leukocyte Surface Antigen CD47 Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific Leukocyte Surface Antigen CD47 Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Leukocyte Surface Antigen CD47 Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America Leukocyte Surface Antigen CD47 Sales Value (2021-2032) & (US$ Million) Figure 42. South America Leukocyte Surface Antigen CD47 Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa Leukocyte Surface Antigen CD47 Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa Leukocyte Surface Antigen CD47 Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Leukocyte Surface Antigen CD47 Value Chain Figure 130. Manufacturing Cost Structure Figure 131. Leukocyte Surface Antigen CD47 Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • PSTx-23
  • CC-90002
  • B-6H12
  • ALX-148
  • Others
Applications
  • Ischemia Reperfusion Injury
  • Kindney Transplant Rejection
  • Ovarian Cancer
  • Lymphoma
  • Others
Companies covered
  • Trillium Therapeutics Inc
  • Surface Oncology Inc
  • Forty Seven Inc
  • Celgene Corp
  • Aurigene Discovery Technologies Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Leukocyte Surface Antigen CD47 Sales Value (2021-2032)
  4. 1.2.2 Global Leukocyte Surface Antigen CD47 Sales Volume (2021-2032)
  5. 1.2.3 Global Leukocyte Surface Antigen CD47 Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Leukocyte Surface Antigen CD47 Market Dynamics
  1. 2.1 Leukocyte Surface Antigen CD47 Industry Trends
  2. 2.2 Leukocyte Surface Antigen CD47 Industry Drivers
  3. 2.3 Leukocyte Surface Antigen CD47 Industry Opportunities and Challenges
  4. 2.4 Leukocyte Surface Antigen CD47 Industry Restraints
3 Leukocyte Surface Antigen CD47 Market by Company
  1. 3.1 Global Leukocyte Surface Antigen CD47 Company Revenue Ranking in 2025
  2. 3.2 Global Leukocyte Surface Antigen CD47 Revenue by Company (2021-2026)
  3. 3.3 Global Leukocyte Surface Antigen CD47 Sales Volume by Company (2021-2026)
  4. 3.4 Global Leukocyte Surface Antigen CD47 Average Price by Company (2021-2026)
  5. 3.5 Global Leukocyte Surface Antigen CD47 Company Ranking (2024-2026)
  6. 3.6 Global Leukocyte Surface Antigen CD47 Company Manufacturing Base and Headquarters
  7. 3.7 Global Leukocyte Surface Antigen CD47 Company Product Type and Application
  8. 3.8 Global Leukocyte Surface Antigen CD47 Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Leukocyte Surface Antigen CD47 Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Leukocyte Surface Antigen CD47 Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Leukocyte Surface Antigen CD47 Market by Type
  1. 4.1 Leukocyte Surface Antigen CD47 Type Introduction
  2. 4.1.1 PSTx-23
  3. 4.1.2 CC-90002
  4. 4.1.3 B-6H12
  5. 4.1.4 ALX-148
  6. 4.1.5 Others
  7. 4.2 Global Leukocyte Surface Antigen CD47 Sales Volume by Type
  8. 4.2.1 Global Leukocyte Surface Antigen CD47 Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Leukocyte Surface Antigen CD47 Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Leukocyte Surface Antigen CD47 Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Leukocyte Surface Antigen CD47 Sales Value by Type
  12. 4.3.1 Global Leukocyte Surface Antigen CD47 Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Leukocyte Surface Antigen CD47 Sales Value by Type (2021-2032)
  14. 4.3.3 Global Leukocyte Surface Antigen CD47 Sales Value Share by Type (2021-2032)
5 Leukocyte Surface Antigen CD47 Market by Application
  1. 5.1 Leukocyte Surface Antigen CD47 Application Introduction
  2. 5.1.1 Ischemia Reperfusion Injury
  3. 5.1.2 Kindney Transplant Rejection
  4. 5.1.3 Ovarian Cancer
  5. 5.1.4 Lymphoma
  6. 5.1.5 Others
  7. 5.2 Global Leukocyte Surface Antigen CD47 Sales Volume by Application
  8. 5.2.1 Global Leukocyte Surface Antigen CD47 Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Leukocyte Surface Antigen CD47 Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Leukocyte Surface Antigen CD47 Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Leukocyte Surface Antigen CD47 Sales Value by Application
  12. 5.3.1 Global Leukocyte Surface Antigen CD47 Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Leukocyte Surface Antigen CD47 Sales Value by Application (2021-2032)
  14. 5.3.3 Global Leukocyte Surface Antigen CD47 Sales Value Share by Application (2021-2032)
6 Leukocyte Surface Antigen CD47 Regional Sales and Value Analysis
  1. 6.1 Global Leukocyte Surface Antigen CD47 Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Leukocyte Surface Antigen CD47 Sales by Region (2021-2032)
  3. 6.2.1 Global Leukocyte Surface Antigen CD47 Sales by Region: 2021-2026
  4. 6.2.2 Global Leukocyte Surface Antigen CD47 Sales by Region (2027-2032)
  5. 6.3 Global Leukocyte Surface Antigen CD47 Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Leukocyte Surface Antigen CD47 Sales Value by Region (2021-2032)
  7. 6.4.1 Global Leukocyte Surface Antigen CD47 Sales Value by Region: 2021-2026
  8. 6.4.2 Global Leukocyte Surface Antigen CD47 Sales Value by Region (2027-2032)
  9. 6.5 Global Leukocyte Surface Antigen CD47 Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Leukocyte Surface Antigen CD47 Sales Value (2021-2032)
  12. 6.6.2 North America Leukocyte Surface Antigen CD47 Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Leukocyte Surface Antigen CD47 Sales Value (2021-2032)
  15. 6.7.2 Europe Leukocyte Surface Antigen CD47 Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Leukocyte Surface Antigen CD47 Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Leukocyte Surface Antigen CD47 Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Leukocyte Surface Antigen CD47 Sales Value (2021-2032)
  21. 6.9.2 South America Leukocyte Surface Antigen CD47 Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Leukocyte Surface Antigen CD47 Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Leukocyte Surface Antigen CD47 Sales Value Share by Country, 2025 VS 2032
7 Leukocyte Surface Antigen CD47 Country-level Sales and Value Analysis
  1. 7.1 Global Leukocyte Surface Antigen CD47 Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Leukocyte Surface Antigen CD47 Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Leukocyte Surface Antigen CD47 Sales by Country (2021-2032)
  4. 7.3.1 Global Leukocyte Surface Antigen CD47 Sales by Country (2021-2026)
  5. 7.3.2 Global Leukocyte Surface Antigen CD47 Sales by Country (2027-2032)
  6. 7.4 Global Leukocyte Surface Antigen CD47 Sales Value by Country (2021-2032)
  7. 7.4.1 Global Leukocyte Surface Antigen CD47 Sales Value by Country (2021-2026)
  8. 7.4.2 Global Leukocyte Surface Antigen CD47 Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Leukocyte Surface Antigen CD47 Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Leukocyte Surface Antigen CD47 Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Leukocyte Surface Antigen CD47 Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Trillium Therapeutics Inc
  2. 8.1.1 Trillium Therapeutics Inc Company Information
  3. 8.1.2 Trillium Therapeutics Inc Business Overview
  4. 8.1.3 Trillium Therapeutics Inc Leukocyte Surface Antigen CD47 Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Trillium Therapeutics Inc Leukocyte Surface Antigen CD47 Product Portfolio
  6. 8.1.5 Trillium Therapeutics Inc Recent Developments
  7. 8.2 Surface Oncology Inc
  8. 8.2.1 Surface Oncology Inc Company Information
  9. 8.2.2 Surface Oncology Inc Business Overview
  10. 8.2.3 Surface Oncology Inc Leukocyte Surface Antigen CD47 Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Surface Oncology Inc Leukocyte Surface Antigen CD47 Product Portfolio
  12. 8.2.5 Surface Oncology Inc Recent Developments
  13. 8.3 Forty Seven Inc
  14. 8.3.1 Forty Seven Inc Company Information
  15. 8.3.2 Forty Seven Inc Business Overview
  16. 8.3.3 Forty Seven Inc Leukocyte Surface Antigen CD47 Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Forty Seven Inc Leukocyte Surface Antigen CD47 Product Portfolio
  18. 8.3.5 Forty Seven Inc Recent Developments
  19. 8.4 Celgene Corp
  20. 8.4.1 Celgene Corp Company Information
  21. 8.4.2 Celgene Corp Business Overview
  22. 8.4.3 Celgene Corp Leukocyte Surface Antigen CD47 Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Celgene Corp Leukocyte Surface Antigen CD47 Product Portfolio
  24. 8.4.5 Celgene Corp Recent Developments
  25. 8.5 Aurigene Discovery Technologies Ltd
  26. 8.5.1 Aurigene Discovery Technologies Ltd Company Information
  27. 8.5.2 Aurigene Discovery Technologies Ltd Business Overview
  28. 8.5.3 Aurigene Discovery Technologies Ltd Leukocyte Surface Antigen CD47 Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Aurigene Discovery Technologies Ltd Leukocyte Surface Antigen CD47 Product Portfolio
  30. 8.5.5 Aurigene Discovery Technologies Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Leukocyte Surface Antigen CD47 Value Chain Analysis
  2. 9.1.1 Leukocyte Surface Antigen CD47 Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Leukocyte Surface Antigen CD47 Sales Mode & Process
  6. 9.2 Leukocyte Surface Antigen CD47 Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Leukocyte Surface Antigen CD47 Distributors
  9. 9.2.3 Leukocyte Surface Antigen CD47 Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst